Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 25,000 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the transaction, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Sensei Biotherapeutics Stock Down 6.4%

NASDAQ SNSE opened at $19.79 on Tuesday. Sensei Biotherapeutics, Inc. has a 52-week low of $5.60 and a 52-week high of $36.76. The business’s 50-day moving average price is $26.20 and its 200 day moving average price is $18.61. The firm has a market cap of $26.52 million, a P/E ratio of -0.14 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). As a group, analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SNSE. Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics during the 1st quarter valued at approximately $22,758,000. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics during the 1st quarter valued at approximately $4,188,000. Bank of America Corp DE lifted its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares during the period. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SNSE shares. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Cantor Fitzgerald started coverage on Sensei Biotherapeutics in a report on Friday. They issued an “overweight” rating on the stock. Leerink Partners started coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective on the stock. Loop Capital set a $50.00 price objective on Sensei Biotherapeutics in a report on Thursday. Finally, Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensei Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $46.25.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.